Thiopurine S-methyltransferase polymorphism in the Thai population

British Journal of Clinical Pharmacology

Volumn 58, Issue 1, 2004, Pages 66-70

  Srimartpirom, Somrudee ^a   Tassaneeyakul, Wongwiwat ^b   Kukongviriyapan, Veerapol ^a   Tassaneeyakul, Wichittra ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Genetic polymorphism; Thai; Thiopurine S methyltransferase; TPMT

Indexed keywords

GENOMIC DNA; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; DNA ISOLATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOCYTE; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THAILAND;

ADULT; FEMALE; GENE FREQUENCY; HOMOZYGOTE; HUMANS; MALE; METHYLTRANSFERASES; MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THAILAND;

EID: 3142594219     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02112.x     Document Type: Article

References (26)

1. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-46.
2. Weinshilboum RM. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-5.
3. Leonard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9.
4. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-8.
5. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
6. Weinshilboum RM, Sladek S. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methylatransferase activity. Am J Hum Genet 1980; 32: 651-62.
7. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001; 1: 254-61.
8. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92: 949-53.
9. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702.
10. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
11. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
12. Ando M, Ando Y, Hasegawa Y, Shekido Y, Shimokata K, Horibe K. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese with acute lymphoblastic leukaemia. Pharmacogenetics 2001; 11: 269-73.
13. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F, et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999; 9: 189-98.
14. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of Thiopurine methytransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
15. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001; 11: 275-8.
16. Hongeng S, Sasanakul W, Chuansumrit A, Pakakasama S, Chattananon A, Hathirat P. Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol 2000; 35: 410-4.
17. Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South- east Asian populations. Pharmacogenetics 2002; 12: 191-5.
18. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics 2002; 12: 221-5.
19. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
20. Tai HL, Fessing MY, Bonten EJ, et al. Enhanced proteasomal degradation of mutant human thiopurine S- methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999; 9: 641-50.
21. Nishida A, Kubota T, Yamada Y, et al. Thiopurine S-methyltransferase activity in Japanese subjects: metabolic activity of 6-mercaptopurine 6-methylation in different TPMT genotypes. Clin Chim Acta 2002; 323: 147-50.
22. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-6.
23. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
24. Tassaneeyakul W, Srimartpirom S, Reungjui S, Chunsung K, Romphruk A, Tassaneeyakul W. Azathioprine-induced fatal myelosuppression in a renal transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 2003; 76: 265-6.
25. McLeod HL, Pritchard SC. Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9: 773-6.
26. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367-70.